

Editorial commentary

391 Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
M Koch

Multiple sclerosis

392 Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)

A A Toorop, Z YGJ van Lierop, L MY Gelissen, E Hoitsma, E MPE Zeinstra, L C van Rooij, C EP van Munster, A Vennegoor, J P Mostert, B HA Wokke, N F Kalkers, E LJ Hoogervorst, J JJ van Eijke, C M Roosendaal, J J Kragt, M Eurelings, J van Genugten, J Nielsen, LGF Sinnige, M E Kloosterziel, E PJ Arnoldus, G W van Dijke, W H Bouvy, M HJ Wessels, L Boonkamp, E MM Strijbis, B W van Oosten, B A De Jong, B I Lissenberg-Witte, F Barkhof, B Moraal, C E Teunissen, T Rispens, B MJ Uitdehaag, J Killestein, Z LE van Kempen

401 Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting
A J Palmer, T Zhao, B V Taylor, I van der Mei, J A Campbell

410 Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis
N Fissolo, P Benkert, J Sastre-Garriga, N Mongay-Ochoa, A Vilaseca-Jolonch, S Llufrú, Y Blanco, H Hegen, K Bereke, F Perez-Miralles, K Rejdak, L M Villar, E Monreal, R Alvarez-Lafuente, O K Soylu, A Abdelhak, F Bachhuber, H Tumani, S Martínez-Yélamos, A J Sánchez-López, A García-Merino, L Gutiérrez, T Castillo-Trivino, J Lycke, I Rosenstein, R Furlan, M Filippi, N Téllez, L Ramió-Torrentà, J D Lünemann, H Wiendl, S Eichau, M Khalil, J Kuhle, X Montalban, M Comabella

419 Predictive value of retinal atrophy for cognitive decline across disease duration in multiple sclerosis
S Alba-Arbalat, E Solana, E Lopez-Soley, A Camos-Carreras, E Martinez-Heras, F Vivó, I Pulido-Valdeolivas, M Andorra, M Sepulveda, J M Cabrera, E Fonseca, A Calvi, R Alcubierre, M Dotti-Boada, A Saiz, E H Martinez-Lapiscina, P Villoslada, Y Blanco, B Sanchez-Dalmau, S Llufrú

426 Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course
O Abdel-mannan, D Champsas, C Tur, V Lee, S Manivannan, H Usman, A Skjæppen, I Desai, M Chitre, R Forsyth, R Kneen, D Ram, S Ramdas, T Rossor, S West, S Wright, J Palace, E Wassmer, C Hemingway, M J Lim, K Mankad, O Ciccarelli, Y Hacohen, on behalf of the UK-Childhood Neuroinflammatory Disease Network

Neuromuscular

434 Use, tolerability, benefits and side effects of orthotic devices in Charcot-Marie-Tooth disease
A Bertini, F Manganelli, G M Fabrizi, A Schenone, L Santoro, T Cavallaro, M Taghiapietra, M Grandis, S C Previtali, Y M Falzone, I Allegri, L Padua, C Pazzaglia, I Tramacere, E Cavalca, P Saveri, A Quattrone, P Valentino, S Tozza, L Gentile, M Russo, A Mazzeo, G Vita, V Prada, R Zuccarino, F Ferraro, C Pisciotto, D Pareyson, for the Italian CMT Network

Editor Karen Furie (USA)
Deputy Editor Nick Ward (UK)
Associate Editors Aisling Carr (UK), Alan Carson (UK), Liz Coulthard (UK), Sofia Eriksson (UK), Ritsuko Hanajima (Japan), Bruce V Taylor (Australia), Peter Warnke (USA)
Commissioning Editor William Powers (USA)
Social Media Editor Hanna Kristiina Isotalu (UK)
Podcast Editor Saima Chaudhry (USA)
Editors, Practical Neurology Geraint Fuller (UK), Phil Smith (UK)
Editorial Office Journal of Neurology Neurosurgery & Psychiatry
BMJ Publishing Group Ltd BMA House Tavistock Square London WC1H 9JR, UK
E: jnnp@bmj.com
X: @JNNP_BMJ
ISSN: 0022-3050 (print)
ISSN: 1468-330X (online)
Impact factor: 11

Disclaimer: The Editor of JNNP has been granted editorial freedom and JNNP is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. JNNP is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by JNNP does not imply endorsement. BMJ Publishing Group Limited shall not be liable for any loss, injury or damage howsoever arising from JNNP (except for liability which cannot be legally excluded).

Copyright: © 2024 BMJ Publishing Group Ltd. All rights reserved; no part of this publication may be reproduced in any form without permission.

JNNP is published by BMJ Publishing Group Ltd, typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper from sustainable forests.

Journal of Neurology Neurosurgery & Psychiatry ISSN 0022-3050 (USPS 2156) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to Journal of Neurology Neurosurgery & Psychiatry, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London Air Business Ltd is acting as our mailing agent.

MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been chosen in conjunction with the BMJ Patient Forum to be of particular interest to patients and is freely available online.



This article has been made freely available online under the BMJ Journals open access scheme. See http://authors.bmj.com/open-access/



The article is part of the Impact Commentaries series



Member since 2008 JM00010


This journal is a member of and subscribes to the principles of the Committee on Publication Ethics http://publicationethics.org/



When you have finished with this magazine please recycle it.




The online version of this article contains multiple choice questions hosted on BMJ Learning.

- 442** Effectiveness of conservative non-pharmacological interventions in people with muscular dystrophies: a systematic review and meta-analysis
 OPEN ACCESS
E Leone, A Pandyan, A Rogers, R Kulshrestha, J Hill, F Philp

General neurology

- 454** Methodological considerations for observational studies of treatment effectiveness in neurology: a clinician's guide
T Kalincik, I Roos, S Sharmin, C B Malpas


Neuropsychiatry

- 461** Unravelling the influence of affective stimulation on functional neurological symptoms: a pilot experiment examining potential mechanisms
 OPEN ACCESS
S Pick, LS M Millman, E Ward, E Short, B Stanton, AAT S Reinders, J S Winston, T R Nicholson, M J Edwards, L H Goldstein, A S David, T Chalder, M Hotopf, M A Mehta


Epilepsy

- 471** Pragmatic computerised perfusion diagnostics for non-convulsive status epilepticus: a prospective observational study
E Merli, M Romoli, S Galluzzo, L Bevacqua, E S Cece, G Ricci, S Testoni, A Zaniboni, M M Viola, L Simonetti, F Bisulli, S Contardi, P Tinuper, A Zini

Cognition

- 477** Binary reversals: a diagnostic sign in primary progressive aphasia
 OPEN ACCESS
E Mulroy, L B Core, A Chokesuwattanaskul, J CS Johnson, P D Fletcher, C R Marshall, A Volkmer, J D Rohrer, C JD Hardy, M N Rossor, J D Warren

Neurodegeneration

- 481** Clinical biomarker-based biological ageing and future risk of neurological disorders in the UK Biobank
 OPEN ACCESS
J K L Mak, C E McMurrin, S Hägg

PostScript

- 485** Letter